← 홈

CGT · BCMA

87개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 87개
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 7%임상시험 1상태 ACTIVE
CGTBiologicstaleThe First Affiliated Hospital o…Phase 1

Autologous BCMA CAR-T cells and CD19 CAR-T cells (Autologous BCMA CAR-T cells and CD19 CAR-T cells)

Relapsed or Refractory Multiple Myeloma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Autologous BCMA-targeting CAR T cells (Autologous BCMA-targeting CAR T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 96.6%임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

BCMA-CART cells (BCMA-CART cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstalePeking University People's Hosp…Phase 2

BCMA-CD19 CAR-T therapy (BCMA-CD19 CAR-T therapy)

Systemic Lupus Erythematosus; Inflammatory Myopathy · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

BCMA-CS1 cCAR T cells (BCMA-CS1 cCAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleMedical College of WisconsinPhase 1

0.50 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

0.75 x10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

1 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

2.5 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleCells & Genes Biotech (Shanghai…Phase 1

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell (BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell)

Relapsed/Refractory; Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBioray LaboratoriesPreclinical

BCMA-UCART (BCMA-UCART)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleXijing HospitalPhase 1

BCMA/CD19 Dual-Target CAR-T (BCMA/CD19 Dual-Target CAR-T)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

2 / 5 페이지

← 이전다음 →